Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 3Phase 3 2Phase 1 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1

Conditions

Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × futuximab × Clear all
NCT02568046 2019-03-26

Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients

Symphogen A/S

Phase 1/2 Terminated
10 enrolled 14 charts
Gastrointestinal

Colorectal Neoplasms

NCT01117428 2018-10-15

Sym004 in Patients With Advanced Solid Tumors

Symphogen A/S

Phase 1/2 Completed
111 enrolled 18 charts
Gastrointestinal

Colorectal Neoplasms

NCT02924233 2017-08-28

Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer

Symphogen A/S

Phase 1/2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡